The Jackson Laboratory

2018 Presenters

Dawn Barry
arrow

Dawn Barry

President and Co-founder, Luna DNA
close
info:
Ms. Barry is the president and co-founder of Luna DNA, the first genomic andmedical research database owned by its community of data donors. As president,Ms. Barry communicates and implements the company’s vision, mission and overalldirection. She is an esteemed thought leader and veteran of the genomics industry. Prior toLuna DNA, she served as the vice president of Applied Genomics at Illumina, Inc.Ms. Barry integrated market development strategies with product and business modelinnovation to accelerate the application of genomics in medicine and personalhealthcare. She joined Illumina in 2005 as its first market development specialistand held leadership roles in business units, sales and marketing for the company.Ms. Barry spent seven years at Genaissance Pharmaceuticals, one of thefirst genomics startups focused on individualized medicine and DNA-based diagnostictesting. She was named San Diego Business Journal’s 2017 Business Woman of the Year andwas a speaker at TEDxSanDiego 2016. She holds a B.S. in biology from the University ofVermont and an M.B.A. from the University of Connecticut School of Business.
Morris Birnbaum, M.D., Ph.D.
arrow

Morris Birnbaum, M.D., Ph.D.

Senior Vice President and Chief Scientific Officer of Internal Medicinet, Pfizer
close
info:
Dr. Birnbaum completed his undergraduate, graduate and medical training at Brown University in Providence, R.I., before moving to St. Louis to carry out clinical training in Internal Medicine at Barnes Hospital of Washington University School of Medicine. He then performed postdoctoral studies at the University of California, San Francisco and Sloan-Kettering Cancer Institute. Following an associate professorship in the Department of Cell Biology at Harvard Medical School, he moved to the University of Pennsylvania as professor of Medicine and Investigator of the Howard Hughes Medical Institute, where he later became associate dean for Biomedical Cores and associate director of the Institute for Diabetes, Obesity and Metabolism. In 2014, Dr. Birnbaum joined Pfizer Inc. in Cambridge, Mass., as senior vice president and chief scientific officer of CVMET. In 2017, he became the senior vice president and chief scientific officer of Internal Medicine. He was elected to membership in the American Society for Clinical Investigation and Association of American Physicians, and is a fellow of the AAAS. He has served as deputy editor for the Journal of Clinical Investigation and is currently on the Editorial board of Cell Metabolism. His research involves the study of insulin action, metabolism and how organisms respond to both a deficit and a surfeit of food.
Mark S. Blumenkranz, M.D., MMS
arrow

Mark S. Blumenkranz, M.D., MMS

HJ Smead Professor Emeritus, Department of Ophthalmology ,Stanford University
close
info:
Dr. Blumenkranz is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University and the Managing Partner of Lagunita Biosciences an incubator and early stage medical investment company in Silicon Valley. He received his undergraduate and Master’s degrees in Biochemical Pharmacology and M.D. at Brown University. He completed his surgical internship and ophthalmic residency training at Stanford and a fellowship in vitreoretinal diseases at the Bascom Palmer Eye Institute where he was appointed a member of the faculty following completion of his training in 1980. In 1985 he founded the vitreoretinal Fellowship Training Program at the William Beaumont Eye Institute in Royal Oak Michigan, and served as the fellowship director until 1992. He returned to Stanford in 1992 as head of the vitreoretinal service and was appointed to serve as the department chairman from 1997 until 2015. He played a leading role in the planning, fundraising and construction of the Byers Eye Institute at Stanford and served as founding director from September 2010 through June 2015. Dr. Blumenkranz has served on the editorial boards of The American Journal of Ophthalmology, Retina, Ophthalmology and Graefe’s Archives for Ophthalmology. He is a past president of the American University Professors of Ophthalmology (AUPO), the Retina Society and the Macula Society. He is a member of the Steering Committee of the Audacious Goals Initiative of the National Eye Institute (NEI) and a fellow of the Corporation of Brown University where he chairs the Medical School Committee. He has a longstanding interest in academic industrial technology transfer and innovation, and has served as a founder and director of a number of venture-backed private and public medtech and biotech companies.
Ronald Borod
arrow

Ronald Borod

Founder and Principal, Ram Island Strategies
close
info:
Ron Borod, through Ram Island Strategies, provides counseling and advisory services in connection with structuring, rating agency liaison, strategic planning, and management for securitization and structured finance transactions. Mr. Borod focuses primarily on non-traditional asset classes, such as solar and energy efficiency assets, early stage biomedical assets, small business loans, tobacco fee awards and tobacco escrows.
David Botstein, Ph.D.
arrow

David Botstein, Ph.D.

Chief Scientific Officer, Calico
close
info:
Dr. Botstein is a prominent geneticist whose advocacy for gene mapping was crucial in laying the groundwork for the Human Genome Project. He is currently the chief scientific officer of Calico (“California Life Company”). Calico, a biotechnology company focused on longevity and health, was established by Google, Inc. in 2013. He graduated from Harvard and received his Ph.D. from the University of Michigan. He joined the faculty of MIT, rising through the ranks from instructor to professor of Genetics. In 1987 he moved to Genentech, Inc. as Vice President – Science, and in 1990 he joined Stanford University’s School of Medicine, where he was Chairman of the Department of Genetics. In 2003 he joined Princeton as the Anthony Evnin Professor of Genomics and Director of the Lewis-Sigler Institute of Integrative Genomics. Under his leadership, a new graduate program, the Quantitative and Computational Biology program, was established, as well as the Lewis-Sigler Fellow program for early career scientists. David co-taught the Advanced Bacterial Genetics Course at Cold Spring Harbor Laboratory in the 1970s where he also did research while on sabbatical in 1974-1975. Dr. Botstein is a member of the U.S. National Academy of Sciences and the Institute of Medicine. He has served on the NAS/NRC study on the Human Genome Project (1987-88), the NIH Program Advisory Panel on the Human Genome (1989-90), the Advisory Council of the National Center for Human Genome Research (1990-1995) and the Advisory Committee to the Director, National Institutes of Health (2003-2008). He has been a member of the Board of Trustees of Cold Spring Harbor Laboratory and currently Rockefeller University. His numerous awards include the Eli Lilly Award, the Genetics Society of America Medal, the Allen Award of the American Society of Human Genetics, the Dickson Prize, the Rosenstiel Award, the Gruber Prize in Genetics, the Albany Prize, the Dan David Prize and the Breakthrough Prize in Life Sciences.
Christopher Coburn
arrow

Christopher Coburn

CIO, Partners HealthCare System; President, Partners HealthCare International
close
info:
Mr. Coburn leads a team of more than 110 tasked with the worldwide commercial application of the unique capabilities and discoveries of Partners’ faculty and its 73,000 employees. His unit’s business development responsibilities include international consulting, innovation management, industry collaborations, investing, company creation and licensing. Revenue from 2016 commercialization exceeded $118 million. His group guides more than $300 million reserved for investment in companies based on Partners-developed technologies. Prior to joining Partners, Mr. Coburn was the founding director of Cleveland Clinic Innovations and served for 13 years as its executive leader. During his tenure Cleveland Clinic spun off 57 companies that raised more than $700 million in equity financing. Cleveland Clinic had no technology based spin-offs before Coburn’s arrival. He also implemented an innovation alliance network in which Cleveland Clinic directly supports technology commercialization for healthcare systems throughout the United States. Mr. Coburn has been a member of numerous corporate and community boards including Explorys (acquired by IBM), Autonomic Technologies and the U.S. Enrichment Corporation (NYSE:USU). He currently serves on the boards of NEHI and the Museum of Science, Boston (Overseers). He is a former vice president and general manager of Battelle Memorial Institute.
Ora Dar, Ph.D.
arrow

Ora Dar, Ph.D.

Leader, National Infrastructure Platforms for Biotech R&D, Israel Innovation Authority
close
info:
Dr. Dar has 16 years of technological and operational experience, including 13 years of senior management positions as the head of the Life Sciences sector at Israel Innovation Authority and currently as leader of National Infrastructure Platforms for Biotech R&D. She initiated and implemented tools and new incentive platforms required for advancing R&D in Life Sciences companies and for enhancing the technology transfer between academia and industry. Dr. Dar is among the leaders of the National Genomic and Personal Medicine Initiative, including the establishment of a national research-oriented Genomic-Clinical Database of 100K volunteers. Prior to joining the office of the chief scientist, Dr. Dar spent 16 years in academic research, experienced working with industry, and served 10 years as a consultant to local and global venture capital and investment firms. Dr. Dar is a Medical Sciences graduate of the Hebrew University, Jerusalem and holds a Ph.D. from St. Mary’s Hospital Medical School, Imperial College of Science, Technology and Medicine, University of London, UK
Kate Goodrich, M.D., M.H.S.
arrow

Kate Goodrich, M.D., M.H.S.

Director and CMS Chief Medical Officer, Center for Medicare and Medicaid Services
close
info:
Dr. Goodrich joined the Center for Medicare and Medicaid Services in September 2011 where she serves as director of the Quality Measurement and Health Assessment Group in the Center for Clinical Standards and Quality (CCSQ). In this role, she oversees the implementation of 12 quality measurement and public reporting programs and partners with other CMS components on several other programs. She leads a CMS-wide task force to align measures across programs and with the private sector as well as a companion HHS-wide committee. She also co-leads an agency-wide work group to develop the agency’s strategy for quality improvement. Previously, Dr. Goodrich served as a senior advisor to the director of CCSQ and the CMS chief medical officer. From 2010-2011 she served as a medical officer in the office of the assistant secretary for Planning and Evaluation (ASPE) at DHHS where she managed a portfolio of work on comparative effectiveness research and quality measurement and improvement. She is a graduate of the Robert Wood Johnson Clinical Scholars Program at Yale University where she received training in health services research and health policy from 2008-2010. From 1998 to 2008, Dr. Goodrich was on faculty at the George Washington University Medical Center and served as division director for Hospital Medicine from 2005-2008 and was chair of the Institutional Review Board from 2004-2008. She went to medical school at Louisiana State University in Shreveport, La., and completed her internal medicine residency and chief medical resident year at George Washington University Medical Center. She continues to practice clinical medicine as a hospitalist and associate professor of Medicine at George Washington University Hospital.
David Katz, M.D., M.P.H.
arrow

David Katz, M.D., M.P.H.

Founder and President, True Health Initiative
close
info:
Stephen K. Klasko, M.D., M.B.A.
arrow

Stephen K. Klasko, M.D., M.B.A.

President and CEO, Thomas Jefferson University and Jefferson Health
close
info:
As president and CEO of Philadelphia-based Thomas Jefferson University and Jefferson Health since 2013, Dr. Klasko has steered the academic health institutions based on his vision of re-imagining healthcare and higher education. Creating and implementing programs that are shaping the future of healthcare earned him a place on Modern Healthcare’s list of the “100 Most Influential People in Healthcare” and “Most Influential Physician Executives” in 2017. He is a nationally recognized advocate for healthcare transformation, having served as dean of two medical colleges, and leader of three academic health centers prior to becoming president and CEO at Jefferson. He is author of 1999’s The Phantom Stethoscope, 2016’s We CAN Fix Healthcare in America, and editor in chief of the journal “Healthcare Transformation.” His new book is 2018's Bless This Mess: A Picture Story of Healthcare in America. Previously, as CEO of USF Health and dean of the Morsani College of Medicine at the University of South Florida, Dr. Klasko built the “assessment of technical and teamwork competence” center known as CAMLS (Center for Advanced Medical Learning and Simulation). He also led a partnership with the country’s largest retirement community, The Villages, to create “America’s healthiest hometown,” an innovative primary-care-driven, patient-centric, Medicare-based accountable care model. He received his M.D. from Hahnemann University of Philadelphia, and his M.B.A. from the Wharton School of the University of Pennsylvania. Dr. Klasko serves on the board of Teleflex, and has served on both the audit committee and governance committee, and has been a director since 2008. He also is a trustee of Lehigh University
Neil Kumar, Ph.D.
arrow

Neil Kumar, Ph.D.

Chief Executive Officer and Founder, BridgeBio Pharma
close
info:
Dr. Kumar is the CEO of BridgeBio LLC, a company focused on the development of novel therapies for rare genetic disorders. Prior to that, he was a principal at Third Rock Ventures where he supported and managed various portfolio companies in addition to focusing on new company formation and due diligence. He also held the role of vice president, Business Development and Operations for MyoKardia. Prior to joining Third Rock, Dr. Kumar was an associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s personalized medicine efforts. Before joining McKinsey, Dr. Kumar was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. He is the author of several peer-reviewed papers in the fields of oncology and systems biology. Dr. Kumar holds B.S. and M.S. degrees in chemical engineering from Stanford University. He received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.
Daniel Mandell, Ph.D.
arrow

Daniel Mandell, Ph.D.

CEO, GRO Bioscience
close
info:
Wendy Mayer
arrow

Wendy Mayer

Vice President, Worldwide Innovation, Pfizer
close
info:
In addition to her role as vice president, Worldwide Innovation, Ms. Mayer is a member of Pfizer’s Worldwide Business Development and Innovation Leadership Team. In this role, she is responsible for driving innovative ideas and thinking across the organization through the identification of transformative and disruptive innovation platforms that can be leveraged across the business, and through the development of an innovative culture that will support continued innovation throughout the organization. Ms. Mayer joined Pfizer in 1997. Her most recent position was Connecticut state director within Primary Care, responsible for setting and implementing sales strategy across all field promoted brands within the Primary Care business for Connecticut, which accounted for approximately $200 million in revenue. Prior to that she worked as part of the Clinical Trial Excellence initiative. Most of her tenure at Pfizer has been within the Market Analytics organization, most recently as Vice President of Specialty Care Market Analytics. Prior to that she led U.S. Market Analytics, with a focus on all Pfizer brands promoted in the U.S. Before joining Pfizer, Ms. Mayer was a senior consultant at Deloitte & Touche Consulting, focusing on business strategy and process improvement for healthcare clients. She did an administrative fellowship at Northwestern Memorial Hospital in Chicago, and holds a bachelor’s degree and M.B.A. from Cornell University.
Greg Moore, M.D., Ph.D.
arrow

Greg Moore, M.D., Ph.D.

Vice President, Healthcare, Google Cloud
close
info:
Dr. Moore is an engineer (MIT Ph.D.), practicing neuroradiologist, informaticist, and innovator experienced in assembling and inspiring highly talented teams to positively transform healthcare for the benefit of humankind. As Google's senior healthcare leader globally, he leads the healthcare vertical for Google Cloud and partners closely with various Google teams (Brain, Search, Android) and the Alphabet companies in the life sciences domains (Verily, DeepMind, Calico), to guide and develop innovative healthcare products and solutions leveraging machine learning/AI and advanced analytics at scale to positively impact healthcare quality, value, access and delivery globally. Dr. Moore is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his recent leadership appointment at Google, he was chief emerging technology and informatics officer at Geisinger Health System where he also was director of the Institute for Advanced Application.
Henry O’Connell, Ph.D.
arrow

Henry O’Connell, Ph.D.

Founder and CEO, Canary Speech, LLC
close
info:
Content
Aenor Sawyer, M.D.
arrow

Aenor Sawyer, M.D.

Assistant Professor, Orthopaedic Surgery, UCSF School of Medicine
close
info:
Dr. Sawyer combines her skills in Orthopaedics, Physical Therapy, Exercise Physiology and Health Technology to provide comprehensive skeletal health care. She founded and directs the UCSF Skeletal Health Service, which provides bone health care across the life span. Dr. Sawyer founded and co-directs the Pediatric Bone Health Consortium and is editor/author for textbooks in pediatric bone health assessment. In 2011 Dr. Sawyer co-founded (with Pierre Theodore) the Trinity System, a HIPAA compliant, web-based collaboration technology for virtual Tumor Board and multidisciplinary management (MDM) of complex patients. Dr. Sawyer also co-founded MOBI-US, a safe independent mobility device. Prior to joining UCSF she co-developed (with Archinoetics) WEARHUB, a wearable human performance center. As an Expedition Medic for world-record ocean rowers, she employs communication and sensing technologies to provide remote medical coverage. She has also served as an Advisor to Startup Health, Rock Health, Doximity, Epocrates, and early-stage digital health startups. She completed her M.S. and M.D. at UC Davis, her Orthopaedic Surgery Residency at Stanford and her Pediatric Orthopaedic Surgery and Sports Medicine Fellowships in the Harvard Combined Orthopaedic Surgery and Boston Children’s Hospital.
Norman E. “Ned” Sharpless, M.D.
arrow

Norman E. “Ned” Sharpless, M.D.

Director, National Cancer Institute, The National Institutes of Health
close
info:
Dr. Sharpless became the 15th director of the National Cancer Institute (NCI) in 2017. Prior to his appointment, he served as the director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, a position he held since January 2014. He was a Morehead Scholar at UNC–Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction. He then completed his internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston. After two years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics. He became the Wellcome Professor of Cancer Research at UNC in 2012. Dr. Sharpless is a member of the Association of American Physicians as well as the American Society for Clinical Investigation (ASCI), and served on the ASCI council from 2011 to 2014. He was an associate editor of Aging Cell and deputy editor of the Journal of Clinical Investigation. He has authored more than 150 original scientific papers, reviews and book chapters, and is an inventor on 10 patents. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and HealthSpan Diagnostics. In addition to serving as director of NCI, Dr. Sharpless continues his research in understanding the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells.
Geoffrey W. Smith, J.D.
arrow

Geoffrey W. Smith, J.D.

Founder and Managing Partner, Digitalis Ventures
close
info:
Mr. Smith is founder and managing partner of Digitalis Ventures, a venturecapital firm that invests in fundamental new ideas in math and science to addresscomplex health problems. He currently represents Digitalis as a director of CareDoxand GRO Biosciences, and as a board observer of Second Genome. He is also a co-founder and general partner of Ascent Biomedical Ventures, a New York City-based venture capital firm focused on early-stage life sciences investments. He currently represents Ascent on the Board of Directors of Azevan Pharmaceuticals, BackBeat Medical, BlinkBio and Caliber Therapeutics, and is a board observer of Vivasure Medical. Mr. Smith serves as a trustee of The Jackson Laboratory. He is also a member of the Scientific Advisory Board for Brigham & Women’s Hospital in Boston. Previously, he was the founding director of the Mount Sinai Institute of Technology and a professor in the department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Geoff received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.
Michael Snyder, Ph.D.
arrow

Michael Snyder, Ph.D.

Stanford W. Ascherman Professor and Chair, Department of Genetics and Director, Center for Genomics and Personalized Medicine, Stanford University
close
info:
Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These include the development of proteome chips, high-resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high-throughput technologies and RNA-Seq. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of-the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person and used this to assess disease risk and monitor disease states for personalized medicine. He is a co-founder of several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix and Personalis, and he presently serves on the board of a number of companies.
Roger Stein, Ph.D.
arrow

Roger Stein, Ph.D.

Research Affiliate, MIT Laboratory for Financial Engineering and Adjunct professor of Finance New York University, Stern School of Business.
close
info:
Dr. Stein has been actively engaged in developing, implementing and writing about new approaches to applied risk modeling and financial prediction for almost 30 years. He and his teams have developed, implemented and delivered products and services that have become industry benchmarks in banking and finance. He is currently adjunct professor of Finance at NYU’s Stern School of Business and research affiliate at the MIT Laboratory for Financial Engineering. He was perviously senior lecturer in Finance at the MIT Sloan School of Management and is an affiliated researcher at the Center for Risk Management Research, University of California, Berkeley. His current research interests are in the areas of systemic risk, credit risk, model risk and validation, biomedical funding, data science, FinTech and the interface between data mining and financial theory. In addition to his professional work he was the founder and president of the Consortium for Systemic Risk Analytics and a member of the Advisory Council of the Museum of Mathematics; on the Board of PlaNet Finance, USA, and on the Academic Advisory Board of the EC’s SYstemic Risk Tomography Project (SYRTO). Dr. Stein holds a Ph.D. and Master’s degree from the Stern School of Business, New York University, and a Bachelor’s degree in Mathematics and Japanese Studies from the State University of New York at Binghamton.
Steven Steinhubl, M.D.
arrow

Steven Steinhubl, M.D.

Director, Digital Medicine, Scripps Translational Science Institute Associate Professor, Molecular Medicine, The Scripps Research Institute
close
info:
Dr. Steinhubl is the director of Digital Medicine at STSI. He received his undergraduate training in chemical engineering at Purdue University in Indiana, graduate training in physiology at Georgetown University in Washington, D.C., and his medical degree at St. Louis University in Missouri. His internal medicine residency training was completed at David Grant Medical Center at Travis Air Force Base, Calif. Following residency, he was a staff internist at Elmendorf Air Force Base Hospital in Anchorage, Alaska. His cardiology and interventional cardiology fellowships were at the Cleveland Clinic Foundation where he was also chief cardiology fellow. Prior to joining Scripps Steve was the director of Cardiovascular Wellness and the medical director for Employee Wellness for the Geisinger Healthcare System. As the head of the Digital Medicine Division of STSI he leads a research team in the design, development and management of clinical programs built specifically around the novel capabilities of a wide range of digital technologies, including wearable sensors, and big data analytics. His team focuses on the re-imagining of health and healthcare that is made possible through the evidence-based incorporation of digital technologies. Dr. Steinhubl has been active in clinical research for almost 20 years and has been the principal investigator of dozens of national and international trials, and has published over 230 peer-reviewed manuscripts.
Samuel Sternberg, Ph.D.
arrow

Samuel Sternberg, Ph.D.

Assistant Professor, Columbia University
close
info:
Tim Walsh
arrow

Tim Walsh

Chief of Staff, Congressman Juan Vargas
close
info:
Mr. Walsh manages district and legislative offices in San Diego County, Imperial County and in Washington, D.C. He supervises all media relations, legislative strategy and constituent outreach. He has over 15 years of professional experience as a founding member of two companies, at the highest levels of local, state and federal government management, and as an adjunct college professor. He holds undergraduate and graduate degrees from the University of San Diego and a graduate degree from the University of Southern California. He was recently appointed by the mayor of San Diego to the San Diego Housing Commission.